自噬相关SLC24A1 mRNA在胰腺癌的表达及其潜在临床价值

Differential expression of autophagy-related SLC24A1 mRNA in pancreatic cancer and its potential clinical value prediction

目的探究溶质载体24号家族1号成员(solute carrier family 24 member 1,SLC24A1)在胰腺癌中的表达是否具有潜在临床应用价值。方法经体外人胰腺癌细胞实验促进或抑制自噬,分别检测两组胰腺癌细胞株及对照组中SLC24A1的表达值,并绘制自噬促进或抑制组与对照组SLC24A1表达值的散点对比图;通过高通量基因表达数据库(gene expression omnibus data base,GEO)、癌症基因图谱(the cancer genome atlas,TCGA)及基因型及基因表达量关联数据库(genotype-tissue expression,GTEx)联合分析SLC24A1信使核糖核酸(messenger RNA,mRNA)在胰腺癌组织及正常胰腺组织中的表达情况,分析SLC24A1在胰腺癌的差异性表达。结果SLC24A1 mRNA在胰腺癌细胞自噬促进后相对高表达,在胰腺癌细胞自噬受抑制后相对低表达。SLC24A1 mRNA在胰腺腺癌中显著高表达,SMD=0.276[0.002,0.549],差异有统计学意义(P<0.05),且SLC24A1 mRNA在胰腺癌中有较好的区分能力(曲线下面积=0.69[0.65,0.73],敏感度=73%[54%,87%],特异度=56%[37%,73%])。结论SLC24A1可能是诊断胰腺癌的潜在生物标志物,可作为胰腺癌治疗的潜在生物靶点。

Objective To investigate whether the expression of SLC24A1 in pancreatic cancer has potential clinical application value.Methods The expression of SLC24A1 in the two groups of pancreatic cancer cell lines and the control group was detected by promoting or inhibiting autophagy in pancreatic cancer PANC-1 cells in vitro,and the scatter comparison diagram of SLC24A1 expression between the autophagy promoting or inhibiting group and the control group was drawn respectively.The expression of SLC24A1 mRNA in pancreatic cancer tissues and normal pancreatic tissues was jointly analyzed by GEO,TCGA and GTEx databases to further analyze whether the expression of SLC24A1 in pancreatic cancer is different.Results SLC24A1 mRNA expression was relatively high after autophagy promotion in Pancreatic adenocarcinoma(PAAD)cells,and relatively low after autophagy inhibition in pancreatic cancer cells.SLC24A1 mRNA was significantly overexpressed in PAAD,SMD=0.276[0.002,0.549],the result was significantly different(P<0.05),and SLC24A1 mRNA had a good discrimination ability in PAAD(area under curve=0.69[0.65,0.73],sensitivity=73%[54%,87%],specificity=56%[37%,73%]).Conclusion SLC24A1 may be a potential biomarker for the diagnosis of PAAD and a potential biological target for the treatment of PAAD.